Stock Market Reviews

STTK (Shattuck Labs, Inc.) News

Get the latest news, insights, and market updates on STTK (Shattuck Labs, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
  AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February
  Feb 6, 2026 - $STTK
• Why Shattuck Labs Stock Soared in December
  Buttressed by a significant amount of fresh capital, the company is showing progress in the early development of its top investigational drug.
  Jan 6, 2026 - $STTK
• Several Insiders Invested In Shattuck Labs Flagging Positive News
  When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
  Jan 5, 2026 - $STTK
• Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer. The in
  Dec 15, 2025 - $STTK
• Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result
  With strong three-month performance and significant upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our list of the 12 hot penny stocks to invest in right now. Highlighting the SL-325’s Phase 1 readout, expected in Q2 2026, H.C. Wainwright’s Joseph Pantginis reiterated a “Hold” rating on Shattuck Labs, Inc. (NASDAQ:STTK) on November 7, […]
  Nov 29, 2025 - $STTK
• Hedge funds own 27% of Shattuck Labs, Inc. (NASDAQ:STTK) shares but individual investors control 32% of the company
  Key Insights Significant control over Shattuck Labs by individual investors implies that the general public has more...
  Nov 25, 2025 - $STTK
• Shattuck Labs to Participate in Upcoming December Investor Conferences
  AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sa
  Nov 20, 2025 - $STTK
• Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
  –First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. to the Board of Directors – AUSTIN, TX and DURHAM, NC, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor
  Nov 6, 2025 - $STTK
• What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now?
  Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Oct 8, 2025 - $STTK
• Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
  AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The ses
  Oct 2, 2025 - $STTK